209 related articles for article (PubMed ID: 8842274)
1. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt.
Hibbs RG; Weber JT; Corwin A; Allos BM; Abd el Rehim MS; Sharkawy SE; Sarn JE; McKee KT
Clin Infect Dis; 1996 Aug; 23(2):337-40. PubMed ID: 8842274
[TBL] [Abstract][Full Text] [Related]
2. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
[TBL] [Abstract][Full Text] [Related]
3. Foodborne botulism treated with heptavalent botulism antitoxin.
Hill SE; Iqbal R; Cadiz CL; Le J
Ann Pharmacother; 2013 Feb; 47(2):e12. PubMed ID: 23362041
[TBL] [Abstract][Full Text] [Related]
4. Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin.
Fagan RP; Neil KP; Sasich R; Luquez C; Asaad H; Maslanka S; Khalil W
Clin Infect Dis; 2011 Nov; 53(9):e125-8. PubMed ID: 21896700
[TBL] [Abstract][Full Text] [Related]
5. Outbreak of foodborne botulism in Alexandria, Egypt: modulating indications for administration of heptavalent botulinum antitoxin.
Ghitani SA; Ghanem MA; Sultan EA; Atef M; Henaidy MF
Environ Sci Pollut Res Int; 2021 Nov; 28(43):61547-61553. PubMed ID: 34184216
[TBL] [Abstract][Full Text] [Related]
6. Botulism in Spain: Epidemiology and Outcomes of Antitoxin Treatment, 1997-2019.
Peñuelas M; Guerrero-Vadillo M; Valdezate S; Zamora MJ; Leon-Gomez I; Flores-Cuéllar Á; Carrasco G; Díaz-García O; Varela C
Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668823
[TBL] [Abstract][Full Text] [Related]
7. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
Barash JR; Arnon SS
J Infect Dis; 2014 Jan; 209(2):183-91. PubMed ID: 24106296
[TBL] [Abstract][Full Text] [Related]
8. Nine cases of foodborne botulism type B in France and literature review.
Abgueguen P; Delbos V; Chennebault JM; Fanello S; Brenet O; Alquier P; Granry JC; Pichard E
Eur J Clin Microbiol Infect Dis; 2003 Dec; 22(12):749-52. PubMed ID: 14605938
[TBL] [Abstract][Full Text] [Related]
9. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.
Schussler E; Sobel J; Hsu J; Yu P; Meaney-Delman D; Grammer LC; Nowak-Wegrzyn A
Clin Infect Dis; 2017 Dec; 66(suppl_1):S65-S72. PubMed ID: 29293931
[TBL] [Abstract][Full Text] [Related]
10. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
11. A massive outbreak of type E botulism associated with traditional salted fish in Cairo.
Weber JT; Hibbs RG; Darwish A; Mishu B; Corwin AL; Rakha M; Hatheway CL; el Sharkawy S; el-Rahim SA; al-Hamd MF
J Infect Dis; 1993 Feb; 167(2):451-4. PubMed ID: 8421179
[TBL] [Abstract][Full Text] [Related]
12. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
[TBL] [Abstract][Full Text] [Related]
14. Human-derived immune globulins for the treatment of botulism.
Metzger JF; Lewis GE
Rev Infect Dis; 1979; 1(4):689-92. PubMed ID: 399376
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
Barker D; Gillum KT; Niemuth NA; Kodihalli S
PLoS One; 2019; 14(9):e0222670. PubMed ID: 31527885
[TBL] [Abstract][Full Text] [Related]
16. Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.
Rashid EAMA; El-Mahdy NM; Kharoub HS; Gouda AS; ElNabarawy NA; Mégarbane B
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):622-627. PubMed ID: 29786953
[TBL] [Abstract][Full Text] [Related]
17. Outbreak of type E foodborne botulism linked to traditionally prepared salted fish in Ontario, Canada.
Walton RN; Clemens A; Chung J; Moore S; Wharton D; Haydu L; de Villa E; Sanders G; Bussey J; Richardson D; Austin JW
Foodborne Pathog Dis; 2014 Oct; 11(10):830-4. PubMed ID: 25188279
[TBL] [Abstract][Full Text] [Related]
18. Management of botulism.
Robinson RF; Nahata MC
Ann Pharmacother; 2003 Jan; 37(1):127-31. PubMed ID: 12503947
[TBL] [Abstract][Full Text] [Related]
19. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(10):299. PubMed ID: 20300057
[TBL] [Abstract][Full Text] [Related]
20. Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina.
Villar RG; Shapiro RL; Busto S; Riva-Posse C; Verdejo G; Farace MI; Rosetti F; San Juan JA; Julia CM; Becher J; Maslanka SE; Swerdlow DL
JAMA; 1999 Apr; 281(14):1334-8, 1340. PubMed ID: 10208152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
